December 15, 2024
The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately controlled with topical therapies in patients aged 12 years and older, […]
December 13, 2024
Two treatments for children with attention-deficit hyperactivity disorder (ADHD) have been recommended by the European Medicines Agency (EMA) to receive marketing authorizations. Paxneury for ADHD Symptoms […]
December 13, 2024
The European Medicines Agency (EMA) has given a positive recommendation for Rytelo (imetelstat) for the treatment of adult patients with transfusion-dependent anemia due to very low-, […]
December 13, 2024
Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for two drugs for preventing COVID-19: a monoclonal antibody called Kavigale (sipavibart) and […]
December 13, 2024
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Emcitate (tiratricol) for treating peripheral thyrotoxicosis in […]
December 13, 2024
The European Medicines Agency (EMA) has recommended that a new oral agent, Welireg (belzutifan), be granted conditional marketing authorization for treatment of two different diseases: the […]
December 13, 2024
The European Medicines Agency (EMA) has recommended extending the use of Ofev (nintedanib) to include treating progressive fibrosing interstitial lung diseases (ILDs) in children and adolescents […]
December 13, 2024
The European Medicines Agency (EMA) has recommended granting marketing authorization for Seladelpar Gilead (seladelpar lysine dihydrate) to treat primary biliary cholangitis (PBC). PBC is a chronic […]
December 4, 2024
The US Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus) as an intravenous infusion for the treatment of certain adults with […]